Nuvalent (NASDAQ:NUVL) Coverage Initiated at Wells Fargo & Company

Stock analysts at Wells Fargo & Company began coverage on shares of Nuvalent (NASDAQ:NUVL) in a research report issued to clients and investors on Monday. The brokerage set an “overweight” rating and a $116.00 price target on the stock. Wells Fargo & Company‘s target price would suggest a potential upside of 20.01% from the stock’s previous close.

A number of other analysts also recently weighed in on NUVL. Cantor Fitzgerald upped their target price on shares of Nuvalent from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Friday, February 27th. JPMorgan Chase & Co. decreased their target price on shares of Nuvalent from $147.00 to $145.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. UBS Group reiterated a “buy” rating on shares of Nuvalent in a report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a research report on Thursday, January 22nd. Sixteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $137.25.

Nuvalent Price Performance

Shares of NUVL stock opened at $96.66 on Monday. The business’s fifty day moving average is $101.87 and its 200 day moving average is $98.42. The stock has a market cap of $7.60 billion, a price-to-earnings ratio of -16.52 and a beta of 1.32. Nuvalent has a twelve month low of $55.53 and a twelve month high of $113.01.

Insider Activity

In other news, CEO James Richard Porter sold 9,543 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $97.16, for a total transaction of $927,197.88. Following the sale, the chief executive officer owned 278,629 shares in the company, valued at $27,071,593.64. This represents a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Christopher Durant Turner sold 3,181 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $97.16, for a total transaction of $309,065.96. Following the sale, the insider directly owned 55,130 shares of the company’s stock, valued at $5,356,430.80. This trade represents a 5.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 69,379 shares of company stock valued at $6,940,982. Company insiders own 10.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. RA Capital Management L.P. purchased a new stake in shares of Nuvalent during the third quarter valued at $107,794,000. Wellington Management Group LLP lifted its stake in Nuvalent by 46.0% during the 3rd quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after acquiring an additional 724,491 shares during the period. Vanguard Group Inc. lifted its stake in Nuvalent by 13.9% during the 4th quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock valued at $527,521,000 after acquiring an additional 639,264 shares during the period. Norges Bank purchased a new stake in shares of Nuvalent during the 4th quarter valued at about $57,763,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Nuvalent by 32.9% during the 4th quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock valued at $221,826,000 after acquiring an additional 545,542 shares during the last quarter. 97.26% of the stock is owned by institutional investors.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.